Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)
China
· Delayed Price · Currency is CNY 62.94
-0.20 (-0.32%)
At close: Dec 5, 2025
SHA:688192 Revenue
Dizal (Jiangsu) Pharmaceutical had revenue of 231.30M CNY in the quarter ending September 30, 2025, with 71.46% growth. This brings the company's revenue in the last twelve months to 607.75M, up 55.98% year-over-year. In the year 2024, Dizal (Jiangsu) Pharmaceutical had annual revenue of 359.90M with 294.24% growth.
Revenue (ttm)
607.75M
Revenue Growth
+55.98%
P/S Ratio
47.76
Revenue / Employee
713.32K
Employees
852
Market Cap
29.03B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 30.98B |
| WuXi AppTec | 43.88B |
| Shenzhen Mindray Bio-Medical Electronics | 33.07B |
| Sichuan Biokin Pharmaceutical | 2.23B |
| Shanghai United Imaging Healthcare | 12.20B |
| Aier Eye Hospital Group | 22.17B |
| Zhangzhou Pientzehuang Pharmaceutical., | 9.78B |
| Yunnan Baiyao Group Co.,Ltd | 40.77B |